NEW SERVICE: Oligonucleotide ADME/DMPK Characterization
We are excited to announce the expansion of our service portfolio […]
Are you curious to know what existing Admescope customers say about working with us?
The decision of which CRO to work with can have a […]
Are you looking for in vivo DMPK data to support your project?
In vivo characterization is critical at various stages of the drug […]
Don’t wait until it’s too late to consider drug-drug interactions: Enzyme inhibition and induction evaluation
Patients are often treated with multiple simultaneous medications, which generates a […]
Quantitative bioanalysis: your project, our team of experts!
High-quality bioanalytical capabilities are one of the cornerstones in ADME/DMPK research. […]
Admescope increases capacity and capability in high-quality service production through new investments
As summer draws to a close, the Admescope team has been […]
Remember to characterize the physicochemical parameters of your compounds early on
Physicochemical parameters give valuable information about the drug-likeness of the molecules. Solubility […]
Symeres acquires Organix Inc., adding lipids expertise and a strategic foothold in the US
SYMERES PRESS RELEASE Nijmegen, The Netherlands – April 26, 2022: Symeres, […]
Is your drug development program lacking in vitro drug-drug interaction data?
We can support you with the safety evaluation required for investigational […]
In vivo metabolite identification and safety evaluation of human metabolites
To support understanding whether the drug metabolites can be considered safe, […]
New article on physiologically based pharmacokinetic modeling
Admescope’s top expert on physiologically based pharmacokinetic (PBPK) modeling, Dr Aki Heikkinen, […]
Admescope team welcomes a new CEO!
We are excited to announce Admescope team growing with an appointment of Dr […]
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.